The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

17 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.EBI
Columbia University Medical Center
Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.EBI
Albany Molecular Research
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.EBI
Amgen
Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.EBI
National University of Ireland
Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities.EBI
Albany College of Pharmacy and Health Sciences
Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.EBI
Albany College of Pharmacy and Health Sciences
Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis.EBI
Albany College of Pharmacy and Health Sciences
FOUR-MEMBERED FUSED RING COMPOUND AND PREPARATION METHOD AND USE THEREOFBDB
Jiangsu Hansoh Pharmaceutical Group
Substituted benzene compoundsBDB
Epizyme
Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitorsBDB
H. Lundbeck
Substituted pyrrolidines as G-protein coupled receptor 43 agonistsBDB
Epics Therapeutics
Kv1.3 inhibitors and their medical applicationsBDB
4Sc
Pyridine-2-amides useful as CB2 agonistsBDB
Hoffmann-La Roche
Fused heterocyclic derivatives and methods of useBDB
Amgen
4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitorsBDB
Qilu Pharmaceutical
Mechanisms of Osteoclastogenesis Inhibition by a Novel Class of Biphenyl-Type Cannabinoid CB(2) Receptor Inverse Agonists.BDB
University of Bern